Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SLE
MCID: LPS004
MIFTS: 61

Lupus Erythematosus (SLE)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lupus Erythematosus

About this section

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 12 74 52 54 15 71 32
Lupus 12 52 15
Subacute Cutaneous Lupus 52 71
Disseminated Lupus Erythematosus 52
Lupus Erythematosus, Systemic 71
Systemic Lupus Erythematosus 52
Lupus Erythematosus, Discoid 71
Lupus Vulgaris 71
Discoid Lupus 52
Sle 52

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Skin diseases Immune diseases Blood diseases Nephrological diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8857
ICD9CM 34 695.4
NCIt 49 C27153
SNOMED-CT 67 200936003
ICD10 32 L93
UMLS 71 C0024131 C0024138 C0024141 more
Sources

Summaries for Lupus Erythematosus

About this section
NIH Rare Diseases : 52 Lupus is an autoimmune disease that can affect almost every organ in the body. Symptoms of lupus can range from very mild to life-threatening. There are three main types of lupus; systemic lupus erythematosus , discoid lupus , and drug-induced lupus. Symptoms may include pain or swelling in joints, muscle pain, fever, red rashes, most often on the face (also called the "butterfly rash"), hair loss, chest pain, sensitivity to the sun, swelling in legs or around the eyes, and feeling tired. Genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors . Studies suggest that a number of different genes may be involved in determining a person's likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. Lupus is more common in young women. The treatment of lupus depends on the severity of the condition and what parts of the body are affected. Treatment may include acetaminophen , ibuprofen , antimalarial drugs, anti-inflammatory steroids, immunosuppressive drugs, and other such as BLyS-specific inhibitors (Belimumab ).

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to systemic lupus erythematosus 16 and cutaneous lupus erythematosus, and has symptoms including rashes, seizures and pruritus. An important gene associated with Lupus Erythematosus is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and skin, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An autoimmune hypersensitivity disease that is characterized by a constellation of findings that include elevated antibodies to nuclear antigens, antiphospholipids, low complement levels, ulcers, non-scarring alopecia, renal or neurologic damage, and low white blood cell and platelet counts, has symptom rashes, fatigue, arthritis, hair loss, seizures, and symptoms related to affected organs, and has material basis in autoimmune disorder.

Wikipedia : 74 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Sources

Related Diseases for Lupus Erythematosus

About this section

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2323)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 35.5 DNASE1L3 DNASE1 C4A C1QA
2 cutaneous lupus erythematosus 35.5 TRIM21 IRF5 CTLA4
3 neonatal lupus erythematosus 35.4 TRIM21 C4A
4 subacute cutaneous lupus erythematosus 35.2 TRIM21 C1QA
5 systemic lupus erythematosus 35.1 TRIM21 TNFSF4 TLR5 STAT4 SSB SNRPB
6 pediatric systemic lupus erythematosus 35.0 STAT4 C4B C4A
7 vitiligo-associated multiple autoimmune disease susceptibility 1 34.6 PTPN22 PDCD1 CTLA4 C4B
8 c1q deficiency 33.9 C1QC C1QB C1QA
9 sjogren syndrome 33.7 TRIM21 TNFSF4 SSB
10 aicardi-goutieres syndrome 33.6 TLR5 IRF5 DNASE1L3
11 complement factor i deficiency 33.0 C4B C4A
12 autoimmune disease 32.9 TRIM21 STAT4 PTPN22 PDCD1 IRF5 FCGR2B
13 systemic scleroderma 32.9 TRIM21 STAT4 IRF5
14 exanthem 32.7 TRIM21 PDCD1 CTLA4
15 glomerulonephritis 32.6 C4B C4A C1QC C1QB C1QA
16 thrombocytopenia 32.5 TLR5 PTPN22 PDCD1 FCGR2B CTLA4
17 rheumatoid arthritis 32.3 STAT4 PTPN22 PDCD1 IRF5 FCGR2B CTLA4
18 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.2 PTPN22 CTLA4
19 heart block, congenital 31.8 TRIM21 SSB
20 primary biliary cirrhosis 31.7 TLR5 STAT4 PTPN22 PDCD1 IRF5 CTLA4
21 celiac disease 1 31.6 TLR5 STAT4 SNRPB PTPN22 CTLA4
22 mononeuritis multiplex 31.4 TRIM21 SSB
23 common variable immunodeficiency 31.4 TNFSF4 FCGR2B CTLA4 CR2
24 diabetes mellitus, type i 31.2 TLR5 PTPN22 PDCD1 CTLA4 C4A
25 diffuse scleroderma 31.1 TRIM21 BANK1
26 parotitis 31.0 TRIM21 SSB
27 second-degree atrioventricular block 30.9 TRIM21 SSB
28 limited scleroderma 30.9 TRIM21 SSB IRF5 BANK1
29 xerophthalmia 30.9 TRIM21 SSB
30 behcet syndrome 30.8 TLR5 STAT4 PTPN22 CTLA4 C4A
31 polyclonal hypergammaglobulinemia 30.7 TRIM21 SSB
32 multifocal motor neuropathy 30.6 PTPN22 FCGR2B BANK1
33 complement component 3 deficiency 30.6 C4B C4A
34 bone inflammation disease 30.5 TLR5 PTPN22 CTLA4
35 parotid disease 30.5 TRIM21 SSB
36 complement component 5 deficiency 30.3 C4B C4A
37 third-degree atrioventricular block 30.1 TRIM21 SSB
38 oligoarticular juvenile idiopathic arthritis 30.0 STAT4 PTPN22
39 lupus erythematosus tumidus 13.0
40 discoid lupus erythematosus 13.0
41 drug-induced lupus erythematosus 12.9
42 systemic lupus erythematosus 1 12.9
43 systemic lupus erythematosus 2 12.8
44 systemic lupus erythematosus 10 12.8
45 systemic lupus erythematosus 9 12.8
46 systemic lupus erythematosus 6 12.8
47 systemic lupus erythematosus 11 12.8
48 lupus erythematosus panniculitis 12.7
49 chronic cutaneous lupus erythematosus 12.6
50 systemic lupus erythematosus with hemolytic anemia 1 12.6

Graphical network of the top 20 diseases related to Lupus Erythematosus:



Diseases related to Lupus Erythematosus
Sources

Symptoms & Phenotypes for Lupus Erythematosus

About this section

Symptoms:

12
  • • rashes

UMLS symptoms related to Lupus Erythematosus:


seizures, pruritus, exanthema, heliotrope rash, lupus-like rash

GenomeRNAi Phenotypes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.64 C1QA TRIM21
2 Decreased viability GR00249-S 9.64 FCGR2B IRF5 PDCD1 SNRPB TNFSF4
3 Decreased viability GR00381-A-1 9.64 C1QA PDCD1 SNRPB
4 Decreased viability GR00381-A-2 9.64 C1QA
5 Decreased viability GR00381-A-3 9.64 C1QA PDCD1
6 Decreased viability GR00386-A-1 9.64 FCGR2B SNRPB TNFSF4
7 Decreased viability GR00402-S-2 9.64 C1QA C1QB C4B PDCD1 SNRPB

MGI Mouse Phenotypes related to Lupus Erythematosus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 BANK1 C4B CR2 CTLA4 DNASE1 FCGR2B
2 homeostasis/metabolism MP:0005376 10 C1QA C1QC C4B CR2 CTLA4 DNASE1
3 immune system MP:0005387 9.83 BANK1 C1QA C4B CR2 CTLA4 DNASE1
4 renal/urinary system MP:0005367 9.28 C1QA C4B CR2 DNASE1 FCGR2B PDCD1
Sources

Drugs & Therapeutics for Lupus Erythematosus

About this section

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 456)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
4
Dalteparin Approved Phase 4 9005-49-6
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Lenalidomide Approved Phase 4 191732-72-6 216326
12
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
13
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
14
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
15
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
16
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
17
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
18
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
19
Linaclotide Approved Phase 4 851199-59-2 65351
20
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
21
Sulfamethoxazole Approved Phase 4 723-46-6 5329
22
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
23
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
24
Lifitegrast Approved Phase 4 1025967-78-5
25
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
26
Hydralazine Approved Phase 4 86-54-4 3637
27
Metformin Approved Phase 4 657-24-9 14219 4091
28
Hydroxychloroquine Approved Phase 4 118-42-3 3652
29
Acetaminophen Approved Phase 4 103-90-2 1983
30
Adenosine Approved, Investigational Phase 4 58-61-7 60961
31
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
32
Povidone Approved Phase 4 9003-39-8
33
Simvastatin Approved Phase 4 79902-63-9 54454
34
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
35
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
36
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
37 Fibrinolytic Agents Phase 4
38 calcium heparin Phase 4
39 Anticoagulants Phase 4
40 Thromboplastin Phase 4
41 Angiotensin II Type 1 Receptor Blockers Phase 4
42 Heparin, Low-Molecular-Weight Phase 4
43 Gastrointestinal Agents Phase 4
44 Dermatologic Agents Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
47 Methylprednisolone Acetate Phase 4
48 Antiemetics Phase 4
49 Rosuvastatin Calcium Phase 4 147098-20-2
50 Antitubercular Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1134)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
5 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
6 A Randomized Study Aimed at Comparing Activated Partial Thromboplastin Time and Anti-Xa Activity and in Patients Requiring Unfractionated Heparin Infusion Unknown status NCT03426982 Phase 4 Unfractionated heparin;Unfractionated heparin
7 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo
8 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Completed NCT02953821 Phase 4 Acthar Gel;Placebo Gel
9 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
10 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
11 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
12 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
13 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTAâ„¢ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
14 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
15 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
16 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
18 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Completed NCT01753401 Phase 4 Acthar;Placebo;Steroid Drug
19 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
20 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
21 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
22 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
23 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
24 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
25 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
26 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
27 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
28 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
29 Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
30 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
31 Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis Completed NCT04146220 Phase 4 Prednisolone
32 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
33 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
34 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
35 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
36 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
37 Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis Completed NCT00356473 Phase 4 Atorvastatin
38 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
39 Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
40 To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
41 Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
42 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
43 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
44 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
45 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
46 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
47 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
48 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
49 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
50 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
Cyclosporine
Hydroxychloroquine
Hydroxychloroquine Sulfate
prasterone
Thalidomide
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide
Sources

Genetic Tests for Lupus Erythematosus

About this section
Sources

Anatomical Context for Lupus Erythematosus

About this section

MalaCards organs/tissues related to Lupus Erythematosus:

40
T Cells, B Cells, Skin, Testes, Kidney, Heart, Bone
Sources

Publications for Lupus Erythematosus

About this section

Articles related to Lupus Erythematosus:

(show top 50) (show all 39428)
# Title Authors PMID Year
1
Vaccination, atherosclerosis and systemic lupus erythematosus. 61 54
19880570 2009
2
[Association of interleukin-18 gene polymorphism with genetic susceptibility to systematic lupus erythematosus in Guangxi Zhuang population]. 54 61
18683145 2008
3
Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon. 54 61
17550096 2006
4
Vasculopathy and renal injury in lupus erythematosus: does shedding of the endothelial protein C receptor play a role? 61 54
15954934 2005
5
Sudden sensorineural hearing loss in lupus erythematosus associated with antiphospholipid syndrome: case report and review. 54 61
15825571 2005
6
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients. 54 61
12716380 2003
7
Catalytic heterogenity of polyclonal RNA-hydrolyzing IgM from sera of patients with lupus erythematosus. 54 61
11208354 2000
8
Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. 54 61
10599336 1999
9
Mucocutaneous disease in Arabs with systemic lupus erythematosus: clinical expression and relevance to autoantibodies. 54 61
9863895 1998
10
Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. 54 61
7774062 1995
11
Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. 54 61
8311089 1994
12
Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus. 54 61
1301991 1992
13
Neonatal lupus erythematosus syndrome: analysis of C4 allotypes and C4 genes in 18 families. 61 54
1545698 1992
14
[Anticardiolipin antibodies in cutaneous lupus erythematosus. Incidence and importance as a marker of vascular symptoms]. 54 61
1577600 1992
15
Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. 54 61
2317112 1990
16
Infection-related hospitalization after intensive immunosuppressive therapy among lupus nephritis and ANCA glomerulonephritis patients. 61
32406300 2020
17
Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody. 61
32228220 2020
18
Visual recovery and vascular reperfusion after vaso-occlusive retinopathy from anti-phospholipid syndrome associated with systemic lupus erythematosus. 61
32551401 2020
19
Perceptions of women with systemic lupus erythematosus undergoing high-risk prenatal care: A qualitative study. 61
32447183 2020
20
Congenital onset of neonatal lupus erythematosus. 61
32366515 2020
21
Hypertension and vascular alterations in lupus autoimmunity. 61
32502094 2020
22
Toll-like receptor 7-driven lupus autoimmunity induces hypertension and vascular alterations in mice. 61
32004206 2020
23
Catastrophes due to missing complements: C1q deficiency lupus with Kikuchi-Fujimoto disease and macrophage activation syndrome. 61
31873753 2020
24
Catastrophes due to missing complements: C1q deficiency lupus with Kikuchi-Fujimoto disease and macrophage activation syndrome. 61
32060514 2020
25
Generalized facial pigmentation: An uncommon presentation of cutaneous lupus erythematosus. 61
32461382 2020
26
Childhood subacute cutaneous lupus erythematosus associated with transaminitis. 61
31850540 2020
27
A case of discoid lupus erythematosus because of palbociclib. 61
32222999 2020
28
Periocular discoid lupus erythematosus: diagnostic challenges of a clinical and histopathological masquerader. 61
32048320 2020
29
Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. 61
32193650 2020
30
Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis. 61
32444136 2020
31
Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings. 61
32265078 2020
32
Prevalence of anti-DFS70 autoantibodies in a Latin American cohort of patients with systemic lupus erythematosus and without autoimmune diseases. 61
32086623 2020
33
Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review. 61
32119141 2020
34
Pigmented linear discoid lupus erythematosus following the lines of Blaschko: A retrospective study of a Chinese series. 61
32270767 2020
35
Three cases of subacute cutaneous lupus erythematosus associated with malignancy: a late paraneoplastic phenomenon. 61
31944366 2020
36
A secondary discoid lupus erythematosus induced by scald of edible oil: An illustration of Koebner phenomenon. 61
31660688 2020
37
HIF1α blockade reduces kidney injury in lupus nephritis. 61
32382095 2020
38
Glucocorticoid metabolism in critically ill dogs (Canis lupus familiaris). 61
32169755 2020
39
High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. 61
32462425 2020
40
First report of Thelazia callipaeda in a free-ranging Iberian wolf (Canis lupus signatus) from Spain. 61
32488623 2020
41
B cell depletion in murine lupus using cytotoxic T lymphocytes in vivo: Feasibility and benefit. 61
32408197 2020
42
Posterior Reversible Encephalopathy Syndrome: An Underrecognized Manifestation of Systemic Lupus Erythematosus. 61
32549950 2020
43
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. 61
31642908 2020
44
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. 61
31761943 2020
45
A case of bullous systemic lupus erythematosus presenting both IgG and IgA autoantibodies for collagen VII. 61
32424810 2020
46
Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. 61
32447395 2020
47
Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. 61
32031658 2020
48
The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients. 61
32008155 2020
49
Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. 61
32321721 2020
50
Paediatric systemic lupus erythematosus as a manifestation of constitutional mismatch repair deficiency. 61
31501241 2020
Sources

Variations for Lupus Erythematosus

About this section
Sources

Expression for Lupus Erythematosus

About this section
Search GEO for disease gene expression data for Lupus Erythematosus.
Sources

Pathways for Lupus Erythematosus

About this section

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.84 TRIM21 TNFSF4 TLR5 PTPN22 PDCD1 IRF5
2
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.84 TLR5 STAT4 IRF5 C1QC C1QB C1QA
3
NF-kappaB Signaling 4
12.4 TNFSF4 STAT4 PTPN22 PDCD1 IRF5 CTLA4
4
Creation of C4 and C2 activators 65
Show member pathways
 11.93 C4B C4A C1QC C1QB C1QA
5
Immune response Lectin induced complement pathway 22
Show member pathways
 11.83 CR2 C4B C4A C1QC C1QB C1QA
6
Complement Pathway 63
Show member pathways
 11.63 C4B C4A C1QC C1QB C1QA
7
Complement and coagulation cascades 36 1
11.59 CR2 C4B C4A C1QC C1QB C1QA
8
Pertussis 36
11.54 C4B C4A C1QC C1QB C1QA
9
Prion diseases 36
11.18 C1QC C1QB C1QA
10
Staphylococcus aureus infection 36
11.08 FCGR2B C4B C4A C1QC C1QB C1QA
Sources

GO Terms for Lupus Erythematosus

About this section

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 9.43 C1QC C1QB C1QA
2 collagen trimer GO:0005581 9.33 C1QC C1QB C1QA
3 blood microparticle GO:0072562 9.26 C4B C4A C1QC C1QB
4 complement component C1 complex GO:0005602 8.62 C1QB C1QA

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 TNFSF4 FCGR2B CTLA4 CR2 C1QC
2 inflammatory response GO:0006954 9.91 TNFSF4 TLR5 FCGR2B C4B C4A
3 innate immune response GO:0045087 9.81 TRIM21 TLR5 IRF5 CR2 C4B C4A
4 complement activation, classical pathway GO:0006958 9.73 CR2 C4B C4A C1QC C1QB C1QA
5 complement activation GO:0006956 9.72 C4B C4A C1QC C1QB C1QA
6 regulation of innate immune response GO:0045088 9.6 PTPN22 FCGR2B
7 negative regulation of B cell proliferation GO:0030889 9.59 FCGR2B CTLA4
8 histone mRNA metabolic process GO:0008334 9.58 SSB SNRPB
9 DNA catabolic process, endonucleolytic GO:0000737 9.58 DNASE1L3 DNASE1
10 negative regulation of immune response GO:0050777 9.58 PDCD1 FCGR2B CTLA4
11 regulation of adaptive immune response GO:0002819 9.56 TNFSF4 FCGR2B
12 negative regulation of B cell activation GO:0050869 9.55 FCGR2B BANK1
13 negative regulation of regulatory T cell differentiation GO:0045590 9.54 TNFSF4 CTLA4
14 synapse pruning GO:0098883 9.54 C1QC C1QB C1QA
15 DNA catabolic process GO:0006308 9.52 DNASE1L3 DNASE1
16 positive regulation of apoptotic cell clearance GO:2000427 9.49 C4B C4A
17 neutrophil activation involved in immune response GO:0002283 9.48 DNASE1L3 DNASE1
18 regulation of acute inflammatory response GO:0002673 9.46 DNASE1L3 DNASE1
19 regulation of neutrophil mediated cytotoxicity GO:0070948 9.43 DNASE1L3 DNASE1
20 regulation of complement activation GO:0030449 9.43 CR2 C4B C4A C1QC C1QB C1QA
21 immune system process GO:0002376 9.36 TLR5 PTPN22 PDCD1 IRF5 CTLA4 CR2

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TRIM21 TNFSF4 TLR5 STAT4 SSB SNRPB
2 deoxyribonuclease activity GO:0004536 9.26 DNASE1L3 DNASE1
3 complement binding GO:0001848 8.96 CR2 C4B
4 deoxyribonuclease I activity GO:0004530 8.62 DNASE1L3 DNASE1
Sources

Sources for Lupus Erythematosus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....